Alexander O. Schuth Sells 7,500 Shares of Denali Therapeutics Inc (DNLI) Stock

Share on StockTwits

Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $22.58, for a total value of $169,350.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of DNLI opened at $24.44 on Friday. The stock has a market capitalization of $2.11 billion, a PE ratio of -62.67 and a beta of 2.11. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $25.05.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, March 12th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.90. The business had revenue of $125.68 million for the quarter, compared to analyst estimates of $9.73 million. Denali Therapeutics had a negative return on equity of 7.29% and a negative net margin of 28.06%. As a group, sell-side analysts expect that Denali Therapeutics Inc will post -1.65 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on DNLI. ValuEngine cut Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 29th. Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Thursday, January 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $25.00 price objective on shares of Denali Therapeutics in a research note on Friday, December 7th.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. Northern Trust Corp raised its stake in Denali Therapeutics by 11.2% during the second quarter. Northern Trust Corp now owns 186,934 shares of the company’s stock valued at $2,850,000 after buying an additional 18,885 shares in the last quarter. Wells Fargo & Company MN increased its position in Denali Therapeutics by 24.0% in the 3rd quarter. Wells Fargo & Company MN now owns 69,330 shares of the company’s stock valued at $1,508,000 after acquiring an additional 13,410 shares during the period. JPMorgan Chase & Co. increased its position in Denali Therapeutics by 207.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,554 shares of the company’s stock valued at $229,000 after acquiring an additional 7,120 shares during the period. Wasatch Advisors Inc. increased its position in Denali Therapeutics by 90.4% in the 3rd quarter. Wasatch Advisors Inc. now owns 59,269 shares of the company’s stock valued at $1,289,000 after acquiring an additional 28,138 shares during the period. Finally, Rhumbline Advisers increased its position in Denali Therapeutics by 135.3% in the 3rd quarter. Rhumbline Advisers now owns 38,137 shares of the company’s stock valued at $829,000 after acquiring an additional 21,926 shares during the period. 71.72% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Alexander O. Schuth Sells 7,500 Shares of Denali Therapeutics Inc (DNLI) Stock” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/4223628/alexander-o-schuth-sells-7500-shares-of-denali-therapeutics-inc-dnli-stock.html.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: What is Cost of Capital?

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Syros Pharmaceuticals  Stock Rating Upgraded by BidaskClub
Syros Pharmaceuticals Stock Rating Upgraded by BidaskClub
bluebird bio  PT Set at $122.00 by Cantor Fitzgerald
bluebird bio PT Set at $122.00 by Cantor Fitzgerald
Pangaea Logistics Solutions’  “Buy” Rating Reiterated at Noble Financial
Pangaea Logistics Solutions’ “Buy” Rating Reiterated at Noble Financial
Reviewing Carbon Black  & Its Peers
Reviewing Carbon Black & Its Peers
Reviewing Pioneer Natural Resources  & Petroquest Energy
Reviewing Pioneer Natural Resources & Petroquest Energy
SCYNEXIS Inc  Receives Average Recommendation of “Buy” from Analysts
SCYNEXIS Inc Receives Average Recommendation of “Buy” from Analysts


© 2006-2019 Ticker Report